Verona Pharma (VRNA) announced its shareholders have approved the proposal for Merck (MRK) to acquire the company for $107 per ADS, for a total transaction value of approximately $10B. The transaction is being implemented by a scheme of arrangement under English law and remains subject to the sanction of the High Court of Justice of England and Wales. The court hearing to sanction the scheme has been scheduled for October 6.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA: